Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation

Cornea

Volumn 25, Issue 4, 2006, Pages 443-447

  Cursiefen, Claus ^a,b   Maruyama, Kazuichi ^b   Jackson, David G ^c   Streilein, J Wayne ^b   Kruse, Friedrich E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiogenesis; Cornea; Inflammation; Lymphangiogenesis; Time course

Indexed keywords

CD31 ANTIGEN; CELL MARKER; BIOLOGICAL MARKER; GLYCOPROTEIN; XLKD1 PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA STROMA; CORNEA TRANSPLANTATION; DISEASE COURSE; FEMALE; HIGH RISK PATIENT; IMMUNOHISTOCHEMISTRY; KERATITIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; REMISSION; SURVIVAL; SUTURE; TIME; TREATMENT PLANNING; ANIMAL; BAGG ALBINO MOUSE; CORNEA; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; BIOLOGICAL MARKERS; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLYCOPROTEINS; KERATITIS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MICE; MICE, INBRED BALB C; TIME FACTORS;

EID: 33745026496     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000183485.85636.ff     Document Type: Article

References (29)

1. Küchle M, Cursiefen C, Nguyen NX, et al. Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol. 2002;240:580-584.
2. Streilein JW, Yamada J, Dana MR, et al. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant Proc. 1999;31:1472-1475.
3. Collin HB. Endothelial cell lined lymphatics in the vascularized rabbit cornea. Invest Ophthalmol. 1966;5:337-354.
4. Cursiefen C, Chen L, Dana MR, et al. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea. 2003;22:273-281.
5. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3:879-889.
6. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994;101:1536-1547.
7. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485-2494.
8. Sano Y, Ksander BR, Streilein JW. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci. 1995;36:2176-2185.
9. Streilein JW, Bradley D, Sano Y, et al. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Invest Ophthalmol Vis Sci. 1996;37:413-424.
10. Cursiefen C, Wenkel H, Martus P, et al. Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2001;239:514-521.
11. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45:2666-2673.
12. Cursiefen C, Schlötzer-Schrehardt U, Küchle M, et al. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci. 2002;43:2127-2135.
13. Cursiefen C, Seitz B, Dana MR, et al. Angiogenese und Lymphangiogenese in der Hornhaut: Pathogenese, Klinik und Therapieoptionen. Ophthalmologe. 2003;100:292-299.
14. Liu Y, Hamrah P, Zhang Q, et al. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med. 2002;195:259-268.
15. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004;45:1117-1124.
16. Cursiefen C, Küchle M, Naumann GOH. Angiogenesis in corneal diseases: histopathology of 254 human corneal buttons with neovascularization. Cornea. 1998;17:611-613.
17. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
18. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040-1050.
19. Aussprunk DH, Falterman K, Folkman J. The sequence of events in the regression of corneal capillaries. Lab Invest. 1978;38:284-294.
20. Cursiefen C, Hofmann-Rummelt C, Küchle M, et al. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol. 2003;87:101-106.
21. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med. 2004;10:813-815.
22. Yamagami S, Dana MR. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci. 2001;42:1293-1298.
23. Yamagami S, Dana MR, Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea. 2002;21:405-409.
24. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789-801.
25. Jackson DG, Prevo R, Clasper S, et al. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol. 2001;22:317-321.
26. Paavonen K, Puolakkainen P, Jussila L, et al. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol. 2000;156:1499-1504.
27. Witmer AN, van Blijswijk BC, Dai J, et al. VEGFR-3 in adult angiogenesis. J Pathol. 2001;195:490-497.
28. Chang LK, Garcia-Cardena G, Farnebo F, et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A. 2004;101:11658-11663.
29. Lohela M, Saaristo A, Veikkola T, et al. Lymphangiogenic growth factors, receptors and therapies. Thromb Haemost. 2003;90:167-184.